Trial · NCT01007552
Adverse events247
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 247
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Gemcitabine, Capecitabine and Bevacizumab | 34 | 50 | 399 |
| other | Leukopenia | Blood and lymphatic system disorders | Gemcitabine, Capecitabine and Bevacizumab | 38 | 50 | 837 |
| other | Lymphopenia | Blood and lymphatic system disorders | Gemcitabine, Capecitabine and Bevacizumab | 34 | 50 | 369 |
| other | Neutropenia | Blood and lymphatic system disorders | Gemcitabine, Capecitabine and Bevacizumab | 29 | 50 | 522 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Gemcitabine, Capecitabine and Bevacizumab | 31 | 50 | 435 |
| other | Pericardial effusion | Cardiac disorders | Gemcitabine, Capecitabine and Bevacizumab | 2 | 50 | 6 |
| other | Tachycardia | Cardiac disorders | Gemcitabine, Capecitabine and Bevacizumab | 1 | 50 | 3 |
| other | Ear pain | Ear and labyrinth disorders | Gemcitabine, Capecitabine and Bevacizumab | 1 | 50 | 3 |
| other | Vertigo | Ear and labyrinth disorders | Gemcitabine, Capecitabine and Bevacizumab | 1 | 50 | 3 |
| other | Abnormal sensation in eye | Eye disorders | Gemcitabine, Capecitabine and Bevacizumab | 1 | 50 | 3 |
| other | Cataract | Eye disorders | Gemcitabine, Capecitabine and Bevacizumab | 1 | 50 | 3 |
| other | Dacryostenosis acquired | Eye disorders | Gemcitabine, Capecitabine and Bevacizumab | 1 | 50 | 3 |
| other | Dry eye | Eye disorders | Gemcitabine, Capecitabine and Bevacizumab | 1 | 50 | 3 |
| other | Eye haemorrhage | Eye disorders | Gemcitabine, Capecitabine and Bevacizumab | 1 | 50 | 6 |
| other | Keratitis | Eye disorders | Gemcitabine, Capecitabine and Bevacizumab | 1 | 50 | 3 |
| other | Periorbital oedema | Eye disorders | Gemcitabine, Capecitabine and Bevacizumab | 1 | 50 | 3 |
| other | Photophobia | Eye disorders | Gemcitabine, Capecitabine and Bevacizumab | 2 | 50 | 6 |
| other | Vision blurred | Eye disorders | Gemcitabine, Capecitabine and Bevacizumab | 6 | 50 | 21 |
| other | Vitreous floaters | Eye disorders | Gemcitabine, Capecitabine and Bevacizumab | 1 | 50 | 3 |
| other | Abdominal discomfort | Gastrointestinal disorders | Gemcitabine, Capecitabine and Bevacizumab | 1 | 50 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01007552/events